C21orf37 Polyclonal Antibody, PE Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-15125R-PE |
| Product Name | C21orf37 Polyclonal Antibody, PE Conjugated |
| Applications |
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human |
| Specifications | |
| Conjugation | PE |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human C21orf37 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Subcellular location | Cytoplasm, Nucleus, Extracellular matrix |
| Synonyms | Chromosome 21 open reading frame 37; hCG_1817258; Putative uncharacterized protein C21orf37; CU037_HUMAN. |
| Background | C22orf37 (chromosome 22 open reading frame 37), also known as FLJ40542, is a 170 amino acid protein encoded by a gene located on human chromosome 22, which contains over 500 genes and about 49 million bases. As the second smallest human chromosome, chomosome 22 contains a wide variety of genes with numerous functions. Phelan-McDermid syndrome, Neurofibromatosis type 2 and autism are associated with chromosome 22. A schizophrenia susceptibility locus has been identified on chromosome 22 and studies show that 22q11 deletion symptoms include a high incidence of schizophrenia. Translocations between chromosomes 9 and 22 may lead to the formation of the Philadelphia Chromosome and the subsequent production of the novel fusion protein, BCR-Abl, a potent cell proliferation activator found in several types of leukemia. |
| Application Dilution | |
| IF(IHC-P) | |
| IF(IHC-F) | |
| IF(ICC) | |